Cirium Ascend Consultancy Lands ‘Appraiser of the Year’ Title for the 10th Time
2025 marks the third year in a row Cirium has been awarded the prestigious accolade, recognising their unparalleled expertise in the field
Cirium Ascend Consultancy, part of the world’s most trusted source of aviation analytics, Cirium, has once again landed Airline Economics’ prestigious title of ‘Appraiser of the Year’ at an award ceremony last night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113971776/en/
Cirium awarded 'Appraiser of the Year' (Photo: Business Wire)
This marks the tenth win for Cirium Ascend Consultancy, demonstrating its unparalleled expertise within aviation consultancy and underlining its unwavering commitment to excellence, transparency and accuracy.
The annual award was presented to Rob Morris, Global Head of Cirium Ascend Consultancy, at the Airline Economics Aviation 100 Global Leaders Awards 2025 in Dublin, Ireland, which celebrates the best companies, individuals and transactions in the aviation finance and leasing sector.
2025’s landmark win makes it the first time a single firm has won the title 10 times, recognising Cirium Ascend Consultancy’s invaluable insights that have shaped the strategies of key players in the industry.
Voters of this year’s award praised Cirium’s accurate, timely, and insightful aircraft appraisals that have provided the valuations and analysis needed to understand market outlook, evaluate risks, and identify opportunities.
Rob Morris, Global Head of Cirium Ascend Consultancy, said: “As we start 2025, we are humbled to have been named ‘Appraiser of the Year’ for the tenth time, reaching an impressive milestone in our history.
“Winning this prestigious accolade not only symbolises the trust and confidence our industry has in us, but is a tribute to the Ascend Consultancy team’s dedication and commitment throughout 2024. We have continued to strive for excellence, offering clients independent and transparent insights in a volatile year for OEMs, lessors, and the wider supply chain.”
Cirium Ascend Consultancy’s contributions extend beyond appraisals, encompassing various aspects of aviation analytics such as risk management, asset tracking, and sustainability evaluations. The firm’s innovative solutions, including CO2 emissions benchmarking and fuel consumption analysis, reflect its commitment to supporting the industry’s transition towards a more sustainable future.
With worldwide teams, and the industry’s largest team of ISTAT/ASA certified appraisers, Cirium Ascend Consultancy is poised to further drive industry analysis and improvement in 2025.
To find out more about Cirium Ascend Consultancy visit https://www.cirium.com/analytics-services/ascend-consultancy/
For Cirium media inquiries please contact media@cirium.com
About Cirium Ascend Consultancy
Cirium Ascend Consultancy, a division of Cirium, offers market-leading expertise to help inform and drive successful strategies in the commercial aviation industry. With a global team of seasoned consultants and analysts, Cirium Ascend Consultancy delivers comprehensive data, expert insights, and tailored services that directly impact strategic investments and open avenues for growth in aviation.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.
Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium® on LinkedIn or visit cirium.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113971776/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation to Open New Service Facility at Essendon Fields Airport, Expanding Capabilities in Australia17.2.2025 06:00:00 CET | Press release
Textron Aviation announced today an expansion of its footprint in Australia with the construction of a larger and modernized service facility at Essendon Fields Airport in Melbourne to maximize support for Cessna, Beechcraft and Hawker customers in the region. The new facility will add more space for servicing aircraft, aiding in faster scheduling with minimal down time to keep customers flying. Construction is set to begin March 2025 and Textron Aviation expects to be fully functional in the new facility by early 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213028444/en/ L-R: Stefan Wenger, vice president, International Customer Service Centers, Textron Aviation, Brian Rohloff, senior vice president, Global Customer Support, Textron Aviation, Brendan Pihan, CEO, Essendon Fields Airport, Peter Funder, general manager development, Essendon Fields Airport at the new facility site in Melbourne. (Photo: Craig Moodie)
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)16.2.2025 00:00:00 CET | Press release
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications referencing Prolia and Xgeva, respectivelyMarks Samsung Bioepis’ 10th and 11th product and first endocrinology treatment approved by the EC – adding to its growing portfolio of biosimilars Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars referencing Prolia and Xgeva – formerly referred to as SB16. OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. XBRYK, referencing Xgeva, has been approved for the prevention of skel
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press release
In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “
Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call14.2.2025 19:17:00 CET | Press release
Venture Global, Inc. (“Venture Global”)(NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025. Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year. A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s fir
Asa Gudmundsdottir Wright Award Presented as Plans for New Icelandic Academy of Science & Innovation Announced14.2.2025 17:35:00 CET | Press release
Recognizing Contributions to Science and Innovation Iceland’s President, Halla Tomasdottir, presented the Asa Gudmundsdottir Wright Award at a ceremony at the presidential residence. This year’s recipients are G. Fertram Sigurjonsson, Founder and CEO of Kerecis, and Jon Atli Benediktsson, Rector of the University of Iceland. The award honors individuals who have made significant contributions to science and innovation in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214199674/en/ President Halla Tomasdottir and Kerecis Founder and CEO Fertram Sigurjonsson (Photo: Business Wire) During the ceremony, plans were also announced for the establishment of the Icelandic Academy of Science & Innovation, into which the award recipients will be inducted as members. The academy will provide a platform for collaboration between researchers, entrepreneurs, industry representatives, and academia. It will uphold the tradition o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom